Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Ampol Profit Surges as Refining Margins Hit Record Highs 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
California Seeks Paramount Divestitures in Warner Bros. Merger 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Nvidia Options Price in $280 Billion Earnings Swing 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Tesla Raises Cybertruck Prices by $5,000 in US 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Add as a preferred source on Google
BOTHELL, Wash., April 30, 2018 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its first quarter 2018 financial and operating results after the close of U.S. financial markets on Tuesday, May 8, 2018. Alder management will host a conference call and live audio webcast with accompanying slides to discuss the results and provide a general business update at 5:00 p.m. ET the same day.
The live call may be accessed by dialing (877) 430-4657 for domestic callers or (484) 756-4339 for international callers and providing conference ID number 1767109. The webcast and accompanying slides can be accessed from the Events & Presentations page in the Investors section of Alder's website at www.alderbio.com and will be available for replay following the call for at least 30 days.
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, please visit www.alderbio.com.
Investor Relations Contacts:
Ashwin Agarwal
Vice President, Corporate Strategy
Alder Biopharmaceuticals, Inc.
425-408-8567
[email protected]
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Andy Brimmer / Aura Reinhard / Trevor Gibbons
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
